Thanks for your feedback, this will help us improve our content for you!
Thank for your feedback, this will help us improve our content for you!
Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the development of selinexor for the treatment of multiple myeloma at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter